IRBM Strengthens Position in Neurodegenerative Disease Research Through Extended Collaboration

Published on: 

Pharmaceutical Technology's In the Lab eNewsletter

In the Lab eNewsletter, Pharmaceutical Technology\'s In the Lab eNewsletter-12-05-2018, Volume 13, Issue 12

IRBM has extended its collaboration with CHDI Foundation to progress the development of therapeutics for Huntington's disease.

Italian contract research organization (CRO), IRBM, has extended its collaboration with CHDI Foundation-a non-profit biomedical research organization-to progress the development of therapeutics for Huntington’s disease (HD).

The collaboration, which has been ongoing since 2011, has involved the investigation of innovative therapeutic approaches based on a better understanding of the biology of HD-a genetic neurodegenerative disease that currently has limited treatment options. This extension to the partnership will see IRBM strengthen its expertise in the biology of neurodegenerative diseases, its comprehensive screening capabilities, and its experiences in integrated neuroscience drug discovery with small molecules and biologics.

“We are proud to be involved with this world-leading initiative to improve the quality of life of patients fighting against this terrible disease,” said Piero Di Lorenzo, president and founder of IRBM, in a Nov. 19, 2018 press release. “Together with CHDI we are fully committed to help them: they deserve nothing less than our daily dedication.”


Robi Blumenstein, president of CHDI Management added, “We are delighted to extend CHDI’s collaboration with our colleagues at IRBM. They have made invaluable contributions to a number of our programs and offer important services to the entire HD drug development community.”

Source: IRBM